Merck allergy tablet bests placebo in study

Merck (MRK) says MK-7243, its sublingual allergy immunotherapy tablet, performed better than placebo over the course of the grass pollen season.

"Patients exhibited significant improvement in common allergy symptoms," a study investigator says.

Results on TCS (the sum of of the rhinoconjunctivitis daily symptom score and the daily medication score averaged): MK-7243 group demonstrated a 23% improvement versus placebo (P< .001).

The FDA is reviewing MRK's BLA for the tablets. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs